Biointron Weekly Reports
News??
In our latest episode of the Antibody Basics video series (Part 12), we cover multispecific antibodies as next-generation antibody formats, including examples of tetraspecifics. Watch it now.??
Get ready for the 12th Annual Immuno-Oncology Summit 2024 hosted by Cambridge Healthtech Institute tomorrow from August 7-9 in Philadelphia, PA. This summit explores bi- and multispecific biotherapeutics, CAR T therapies, personalized immunotherapy, overcoming tumor resistance, and AI and machine learning in cancer immunology. Meet us at Booth #8!
?
This Week’s News?
Trends – ADCs: Funding Trends?
Antibody-drug conjugates (ADCs) have revolutionized the landscape of oncology by delivering targeted therapies that minimize damage to healthy cells while maximizing the impact on cancerous tissues. However, researchers and clinicians are now exploring the many therapeutic possibilities of ADCs in treating a variety of non-cancerous conditions such as autoimmune, infectious, neurological, cardiovascular, and metabolic diseases. Oncology often receives considerable R&D funding due to the high incidence of cancer, significant unmet needs, and potential for high returns. Regulatory pathways, competitive landscape, therapeutic potential, strategic fit, partnerships, and financial ROI are essential factors in determining where to invest.?
Various financing deals have been announced this past month, such as:?
A review this week discussed precision targeting in oncology and the future of conjugated drugs. Technological advances have led to a combination of old and new concepts of coupled drugs. For example, antibody-oligonucleotide conjugates (AOCs) are a new class of chimeric biomolecules synthesized by coupling oligonucleotides with monoclonal antibodies through linkers, offering precise targeting and improved pharmacokinetic properties. More choices of localization ligands, linker arms and effector molecules have been realized, which has led to the segmentation of the field and the emergence of many coupled drug forms, such as ribonucleic coupled drug (RDC), small molecule coupled drug (SMDC), peptide coupled drug (PDC), antibody immunostimulant coupled drug (ISAC), antibody fragment coupled drug (FDC), antibody cell coupled drug (ACC), virus-like drug coupling (VDC), antibody oligonucleotide coupling (AOC), and more.
However, developing and manufacturing types of ADCs are challenging due to their complex structure, which requires expertise across multiple disciplines to ensure safety and efficacy. Challenges include optimizing antibodies, cytotoxic drugs, and linkers, achieving consistent conjugation, maintaining molecular integrity, and scaling up production while maintaining quality. Future trends in ADC development include innovations in linkers and payloads, broader therapeutic applications, combination therapies, advanced manufacturing methods, and adaptive regulatory frameworks, all of which will drive further growth and development in the market.?
Upcoming Events?
Next month we will be exhibiting at the 15th World Bispecific Summit on September 3-5 in Boston, MA. The summit is the industry’s one-stop-shop for all your strategic needs within bi, tri or multi-specifics or even bispecific ADCs or BiTEs. Hosted by Hanson Wade Group and held at the Royal Sonesta Boston, we look forward to meeting you!?
领英推荐
Promotions – 40% OFF Abinvivo Products! ???
Save on Your Next Project with Abinvivo Reagents! Biointron is excited to announce a ????% ????????-???????? ???????????????? on our top-quality in vivo reagent products at the Biointron sub-brand, Abinvivo! Now with online check-out and 1 week delivery!?
????????'?? ????????????????:?
?????????????????? ???????????????? ?????????????????
?????????????? ???????????????? ?????????????????
????????-?????????? ?????????????????
???????????????????? ????????????????????
...?????? ????????!?
?? ?????? ???????????? ?????? ?????????????? ??????????????????
Don't miss out on this fantastic opportunity to enhance your research with top-tier reagents at unbeatable prices: https://www.abinvivo.com/abinvivo/Home?
RushMab? - Gene is your go-to solution for quick plasmid production, designed specifically for antibody-related research. We offer a 4-day turnaround, delivering high-quality, transfection-grade expression plasmids for IgG, Fab, VHH, and ScFv sequences. We provide quantities of 100 μg (sufficient for 100 ml culture) with scalability up to grams. Using the reliable pcDNA3.4 backbone, we also accommodate custom vectors. Each plasmid undergoes Sanger sequencing verification and endotoxin control, ensuring precision and safety.
?
New Products & Reports?
Learn more about Biointron at www.biointron.com, or contact us at [email protected] and +1 (732) 790-8340.